SUPN Q4 2024 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$174M+6.0% YoY

Gross Profit

$148M85.0% margin

Operating Income

$21M12.3% margin

Net Income

$15M8.8% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$332M

Stockholders' Equity

$1.0B

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$174M	$164M	+6.0%
Gross Profit	$148M	$145M	+2.3%
Operating Income	$21M	-$996,000	+2249.1%
Net Income	$15M	$1M	+1204.5%

Revenue Segments

Product

$329M49%

Qelbree

$134M20%

GOCOVRI

$69M10%

Oxtellar X R

$43M6%

APOKYN

$37M6%

Trokendi Xr

$32M5%

Royalty, License And Other Revenue

$19M3%

Manufactured Product, Other

$14M2%